Business Wire

NFT Marketplace IOGINALITY Launches, Offering Comprehensive Infrastructure for Digital Art and Bringing Emerging Galleries into the Web3 Fold

22.5.2023 17:33:00 EEST | Business Wire | Press release

Share

IOGINALITY, the first art NFT platform aimed at emerging galleries, today announced its launch to allow galleries and collectors a seamless and fully compliant platform to transact and benefit from the potential of tokenised art.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230522005427/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

IOGINALITY’s interface (Graphic: Business Wire)

Providing emerging galleries with equitable access to resources

With a target of becoming the go-to platform for art market stakeholders worldwide, IOGINALITY’s initial focus is on bringing legal and technical support and resources to young galleries transitioning to the Web3 world, by offering an ecosystem solution and proven legal structure to accelerate new market entrants globally.

IOGINALITY exclusively permits galleries to mint NFTs, guaranteeing that customers deal only with compliant sellers and verified art. In the same vein, IOGINALITY also provides access to trusted buyers by using automated Know-Your-Customer and Know-Your-Business checks, to allow galleries to connect with collectors confidently and provide a trustworthy solution for the financial and legal security of customers’ deals, in line with the ever-evolving regulatory landscape across jurisdictions.

Simplified fee structure for all stakeholders

Powered by smart contracts, IOGINALITY facilitates instantaneous and straightforward transactions for galleries, artists, and art dealers. At the moment of minting, the NFTs’ selling prices and royalties are immediately aligned across all stakeholders, circumventing the costs, obscurities, and delays that often impede innovation. More importantly, the IOGINALITY platform offers the possibility of appointing an unlimited number of receivers involved in the transaction.

Formed under a partnership with Midas Investments, a major international crypto fund based in Hong Kong, IOGINALITY is co-founded by internationally-renowned lawyers Ekaterina Smirnova, and Yuriy Brisov. Together, they bring extensive experience in digital markets, delivering legal, economic and strategic consulting services, as well as a critical awareness of crypto, NFT and securities regulations.

Commenting on the launch, Ekaterina Smirnova, Founder and CEO, said: “IOGINALITY was established as a direct remedy to the common issues facing the NFT market surrounding a lack of transparency, susceptibility to fraud and laundering as well as equitable access to forward-looking legal support resources. As hype around NFTs fades and the professionals remain, the industry is ripe for fundamental transformation. Emerging galleries are repeatedly expressing a keen desire to embrace Web3 and it is important that the industry creates the necessary hand railings to enable their adoption, while setting the standard for accessibility, professionalism, security and trust. IOGINALITY addresses this by levelling the playing field to allow more galleries to join the digital revolution, ushering in a new world order characterised by greater representation.”

Participation from global emerging galleries

At launch, IOGINALITY will first feature collections from Alisa Gallery, a contemporary art gallery in Dubai, imnotART, Chicago’s first NFT art gallery, as well as Web3 creative studio, Wizara. These partnerships allow IOGINALITY to accelerate the market entry of galleries globally, as part of its core mission to enrich an asymmetrical and closed world with quality digital art from all corners of the world. This global presence will be further facilitated by IOGINALITY’s growing network of NFT art ambassadors, who will drive new partnerships between art institutions, brands, and advertisers.

Adham Hafez, Co-founder, Creative Director, and Curator of Wizara added: “As a theorist and a curator, I have been interested in the fact that many legal scholars have moved to study Web3 and engage with how its potentials will radically not only change our understanding of art, but of society and how it manifests itself legally, artistically, politically, and culturally in general. Wizara sees in IOGINALITY a perfect partner in how it straddles an interest in practice as well as in theory, the way it equally invests in not only supporting artists to break through the market, but equally to assist them in understanding the contractual and legal matters of a world governed by Smart-contracts and blockchain-based agreements that will redefine art economy, and many of the gallerist-artists relations in our art worlds today.”

In line with its public launch, IOGINALITY has also launched an open source page ‘NFT Nightmares: Lessons Learned’. Hosted on the IOGINALITY website, the page features key takeaways from high-profile cases of Web3 fraud and malpractice including the stealing of Banksy’s Morons in 2021, and the infamous Hermes vs Rothschld lawsuit, which have deterred many collectors and galleries from exploring this realm. Open for all to participate in and submit personal experiences to feature in the case library, IOGINALITY’s comprehensive platform serves to contribute to the development and betterment of the Web3 community by increasing transparency and awareness of potential pitfalls.

In the long-term, IOGINALITY intends to expand its project and leverage its cross-industry expertise across art, culture, finance, technology, law and project management to implement NFT solutions across markets covering assets such as gems, collectible wines and real estate.

ENDS

About IOGINALITY

IOGINALITY is a digital art marketplace that combines the convenience of the Web3 world with the safety of art dealerships from top galleries and curators to allow artists, institutions, and collectors to transact and benefit from the potential of tokenised art on an accessible, seamless, and fully compliant platform. Through its focus on professionalism and artistic value, IOGINALITY’s platform serves to provide an ecosystem solution to industry concerns around legal, financial and technological facets.

Designed to facilitate greater representation of emerging galleries, IOGINALITY is reimagining the NFT art sector to become the go-to platform for art institutions and stakeholders worldwide to launch digital exhibitions and create NFT collections.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For Media Enquiries
Wachsman
Zuhaili Marican
E: ioginality@wachsman.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Owl Labs partners with Westcoast to expand access to seamless hybrid meeting experiences in the UK and Ireland11.5.2026 10:00:00 EEST | Press release

Owl Labs, a global leader in AI-powered, 360-degree video conferencing solutions, today announced a new UK and Ireland distribution partnership with Westcoast Limited, one of the country’s largest and most trusted IT distributors. The agreement will see Westcoast distribute the full range of Owl Labs’ award-winning Meeting Owl and Owl Bar products across the UK and Ireland, providing greater choice, availability, and dedicated support for resellers and end customers navigating the demands of hybrid work. The partnership aims to address the technical setup challenges that plague meetings across the UK. Owl Labs’ recent State of Hybrid Work report found that nearly 8 in 10 workers (79%) lose time in meetings due to technical difficulties such as connecting to a meeting or setting up a camera. By making Owl Labs’ solutions simpler to source, deploy and support, the Westcoast partnership helps cut the ‘meeting tax’, reducing set‑up friction and getting meetings started on time. The announc

Kiabi Selects Navan to Centralise Global Travel Program11.5.2026 10:00:00 EEST | Press release

Navan (NASDAQ: NAVN), the global AI-powered business travel and expense platform, today announced it has been selected by Kiabi, the French multinational fashion retailer, to consolidate its global travel with one unified platform. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260511547434/en/ Fashion retailer targets high employee adoption and efficiency with AI-powered travel platform To support its workforce of nearly 10,000 “Kiabers,” the retailer required a solution capable of providing an easy-to-use travel platform. Navan was selected due to its intuitive AI-powered interface and ability to integrate with Kiabi’s travel policies directly in-app. “Managing travel was becoming an administrative burden that slowed our teams down,” said Denise Maurice, Indirect Procurement Director at Kiabi. “We wanted to give our ‘Kiabers’ the freedom to book their own trips without getting bogged down in manual approvals. Navan gives t

Fujirebio Announces CE Marking of the Fully Automated Lumipulse® G pTau 217 Plasma Assay11.5.2026 10:00:00 EEST | Press release

H.U. Group Holdings Inc. and its wholly owned subsidiary Fujirebio today announced that Fujirebio Europe N.V. has obtained a CE certificate of the Lumipulse G pTau 217 Plasma assay under the Regulation (EU) 2017/746 on in vitro diagnostic medical devices (IVDR). This CLEIA (chemiluminescent enzyme immunoassay) test allows for the quantitative measurement of Tau phosphorylated at threonine 217 (pTau 217) in human plasma (K2EDTA). “With Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma now CE‑marked on our LUMIPULSE G platform, we are advancing a new era of neurology diagnostics—one where blood‑based biomarkers enable earlier, broader, and more accessible insights into Alzheimer’s disease and neurodegeneration.” said Christiaan De Wilde, CEO at Fujirebio Europe N.V. “By delivering fully automated and scalable solutions, we are helping clinicians move decisively toward more timely and informed decision‑making. This milestone underscores our long‑term vision to reimagine the diagnostic

Mevion Introduces the First Proton Therapy System Designed for a LINAC Vault at ESTRO 202611.5.2026 09:00:00 EEST | Press release

Proton therapy is entering the LINAC vault. At ESTRO 2026, Mevion Medical Systems will introduce the MEVION S250-FIT Proton Therapy System to the European radiation oncology community, the first proton therapy system designed for installation in a standard radiation therapy vault. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507172087/en/ The MEVION S250-FIT™ Proton Therapy System Now both U.S. FDA-cleared and CE-marked under Regulation (EU) 2017/745, the S250-FIT creates a new pathway for cancer centers to bring proton therapy into existing LINAC-based treatment environments, aligning advanced proton capability with the infrastructure, workflows, and capital planning of modern radiation oncology. Stanford Medicine: First S250-FIT Installation On April 7, 2026, Stanford Medicine unveiled the world’s first S250-FIT installation, developed in collaboration with Leo Cancer Care. The system was fully installed within a stan

CORRECTING and REPLACING Samsung Epis Holdings Reports First Quarter 2026 Financial Results11.5.2026 08:10:00 EEST | Press release

Business Updates section, the first bullet of release dated April 23, 2026, at 10:04 p.m. PT/April 24, 2026, at 1:04 a.m. ET should read: In October 2025, Samsung Bioepis entered into a private label partnership with Cordavis for OSPOMYV™ (denosumab-dssb), a biosimilar to Prolia1. The updated release reads: SAMSUNG EPIS HOLDINGS REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS Samsung Epis Holdings (KRX: 0126Z0), an investment company dedicated to innovations in biopharmaceuticals and biotechnology, today announced its financial results for the first quarter of fiscal year 2026. “Samsung Bioepis delivered solid growth this quarter driven by continued momentum across our biosimilar portfolio," said Kyung-Ah Kim, President and Chief Executive Officer (CEO) of Samsung Epis Holdings. “We are further strengthening our position through new global partnerships and continued portfolio expansion. As we mark the 10th anniversary of the launch of our first biosimilar in Europe, we remain focused on b

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye